Zions Bancorporation National Association UT Sells 1,189 Shares of Medpace Holdings, Inc. $MEDP

Zions Bancorporation National Association UT decreased its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,886 shares of the company’s stock after selling 1,189 shares during the quarter. Zions Bancorporation National Association UT’s holdings in Medpace were worth $2,744,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Optiver Holding B.V. bought a new position in Medpace during the 3rd quarter worth approximately $27,000. Steigerwald Gordon & Koch Inc. bought a new position in Medpace during the 4th quarter worth approximately $30,000. Elyxium Wealth LLC bought a new position in Medpace during the 4th quarter worth approximately $30,000. Quarry LP bought a new position in Medpace during the 3rd quarter worth approximately $35,000. Finally, Core Wealth Advisors LLC bought a new position in Medpace during the 4th quarter worth approximately $47,000. Institutional investors own 77.98% of the company’s stock.

Insider Buying and Selling at Medpace

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This trade represents a 44.56% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the sale, the president directly owned 15,000 shares of the company’s stock, valued at approximately $6,829,500. The trade was a 67.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders own 20.50% of the company’s stock.

Medpace Stock Down 0.2%

NASDAQ:MEDP opened at $465.73 on Thursday. The company has a fifty day moving average of $456.97 and a 200-day moving average of $505.72. The firm has a market capitalization of $13.30 billion, a P/E ratio of 29.27, a P/E/G ratio of 2.37 and a beta of 1.18. Medpace Holdings, Inc. has a twelve month low of $294.07 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share for the quarter, beating the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million during the quarter, compared to analyst estimates of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. Medpace’s revenue for the quarter was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. On average, analysts anticipate that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Jefferies Financial Group upgraded shares of Medpace from a “hold” rating to a “buy” rating and set a $560.00 price target for the company in a report on Friday, February 13th. Royal Bank Of Canada lowered their price target on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating for the company in a report on Friday, April 24th. Leerink Partners lowered their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating for the company in a report on Wednesday, February 11th. Wall Street Zen lowered shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, April 25th. Finally, Robert W. Baird lowered their price objective on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating for the company in a research note on Friday, April 24th. Four investment analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Medpace presently has a consensus rating of “Hold” and a consensus target price of $467.08.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.